Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Barclays Sticks to Their Hold Rating for Novo Nordisk (0QIU)

Tipranks - Tipranks - Wed Mar 4, 5:10AM CST

Barclays analyst James Gordon CFA maintained a Hold rating on Novo Nordisk today and set a price target of DKK270.00.

Claim 70% Off TipRanks Premium

According to TipRanks, Gordon CFA is a 3-star analyst with an average return of 7.9% and a 50.00% success rate. Gordon CFA covers the Healthcare sector, focusing on stocks such as Novo Nordisk, Galderma Group AG, and GlaxoSmithKline.

In addition to Barclays, Novo Nordisk also received a Hold from Goldman Sachs’s James Quigley in a report issued yesterday. However, on February 23, Goldman Sachs maintained a Buy rating on Novo Nordisk (LSE: 0QIU).

See Insiders’ Hot Stocks on TipRanks >>

0QIU market cap is currently DKK1054.8B and has a P/E ratio of 10.32.

Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of 0QIU in relation to earlier this year.

Read More on GB:0QIU:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).